Christopher Peetz - 15 Jul 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:07:34 UTC
Prior SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/Latha Vairavan, as Attorney-in-Fact for Christopher Peetz

Key filing fact

Christopher Peetz filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 17 Jul 2026.

Key facts

This page summarizes Christopher Peetz's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Jul 2026, 16:07.

Change

Previous filing in this sequence was filed on 08 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001614740 Primary reporting owner

Peetz Christopher

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/Latha Vairavan, as Attorney-in-Fact for Christopher Peetz
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value
Shares: +4,315
Change %
Price: $0.000000^*
Shares after: 4,315
Date: 15 Jul 2026
Ownership: Direct
Footnotes: F1

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 187,500
Date: 15 Jul 2026
Ownership: By The Peetz Family Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +21,486
Change %
Price: $0.000000^*
Shares after: 21,486
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,486
Exercise price: $27.78
Footnotes: F3

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +13,010
Change %
Price: $0.000000^*
Shares after: 13,010
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,010
Exercise price: $27.78
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.

Footnote F2

Shares held by The Peetz Family Trust dated February 15, 2017, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Footnote F3

1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.

Footnote F4

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.